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ORIGINAL ARTICLE
Cadherin-13, a risk gene for ADHD and comorbid disorders,
impacts GABAergic function in hippocampus and cognition
O Rivero1,9, MM Selten2,3,9, S Sich1,9, S Popp1, L Bacmeister1, E Amendola4, M Negwer2,3, D Schubert2,3, F Proft1, D Kiser1, AG Schmitt5,
C Gross4, SM Kolk6, T Strekalova7, D van den Hove7, TJ Resink8, N Nadif Kasri2,3,10 and KP Lesch1,7,10
Cadherin-13 (CDH13), a unique glycosylphosphatidylinositol-anchored member of the cadherin family of cell adhesion molecules,
has been identiﬁed as a risk gene for attention-deﬁcit/hyperactivity disorder (ADHD) and various comorbid neurodevelopmental
and psychiatric conditions, including depression, substance abuse, autism spectrum disorder and violent behavior, while the
mechanism whereby CDH13 dysfunction inﬂuences pathogenesis of neuropsychiatric disorders remains elusive. Here we explored
the potential role of CDH13 in the inhibitory modulation of brain activity by investigating synaptic function of GABAergic
interneurons. Cellular and subcellular distribution of CDH13 was analyzed in the murine hippocampus and a mouse model with a
targeted inactivation of Cdh13 was generated to evaluate how CDH13 modulates synaptic activity of hippocampal interneurons and
behavioral domains related to psychopathologic (endo)phenotypes. We show that CDH13 expression in the cornu ammonis (CA)
region of the hippocampus is conﬁned to distinct classes of interneurons. Speciﬁcally, CDH13 is expressed by numerous
parvalbumin and somatostatin-expressing interneurons located in the stratum oriens, where it localizes to both the soma and the
presynaptic compartment. Cdh13− /− mice show an increase in basal inhibitory, but not excitatory, synaptic transmission in CA1
pyramidal neurons. Associated with these alterations in hippocampal function, Cdh13− /− mice display deﬁcits in learning and
memory. Taken together, our results indicate that CDH13 is a negative regulator of inhibitory synapses in the hippocampus, and
provide insights into how CDH13 dysfunction may contribute to the excitatory/inhibitory imbalance observed in
neurodevelopmental disorders, such as ADHD and autism.
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INTRODUCTION
Brain development and plasticity are complex processes that
require precise and speciﬁc interneuronal contacts to ensure the
correct establishment of circuits at the cellular and systems level.
To guarantee cellular and regional speciﬁcation of synaptic
contacts, the formation of neuronal networks is tightly controlled
by a myriad of cell guidance and adhesion molecules, among
which the cadherin superfamily of calcium-dependent cell
adhesion molecules is of particular relevance.1 Furthermore, after
development, cadherins regulate the function and plasticity of
mature synapses by participating in synaptic vesicle dynamics or
controlling the stability of synaptic receptors.1
Cadherin-13 (CDH13, also known as T-cadherin or H-cadherin) is
an atypical member of the cadherin superfamily. It lacks both
transmembrane and cytoplasmic domains and is linked to the
plasma membrane via a glycosylphosphatidylinositol moiety.2–4
Genome-wide genetic approaches including linkage analyses,
association studies and copy number variation studies have
detected associations between the CDH13 gene and various
neurodevelopmental disorders. Notably, in several independent
studies, CDH13 has been associated with the risk for attention-
deﬁcit/hyperactivity disorder (ADHD) and frequent comorbid
conditions including drug and alcohol abuse.4–17 In addition,
CDH13 was implicated in depression,7,18 autism spectrum
disorders,19 schizophrenia20 and bipolar disorder.21 Variations in
CDH13 have also been associated with the personality trait of
extraversion22 and extremely violent behavior.23 The mechanism
whereby CDH13 dysfunction contributes to the pathogenesis of
neuropsychiatric conditions remains, however, unknown.
CDH13 is expressed in the developing and adult brain, as well as
in the cardiovascular system, where it exerts its function via low-
adhesive homophilic or heterophilic interactions to control cell
migration, neurite outgrowth and axon guidance.24–29 We there-
fore predicted that CDH13, as several other cell adhesion
molecules, may have dual roles in the brain; speciﬁcally, as a
guidance cue for migrating neurons and/or developing axons, and
as a modulator of the establishment of speciﬁc synaptic contacts
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and function of mature synapses.4 The view that CDH13 may
moderate synapse formation and plasticity is supported by a
previous study,30 showing that Cdh13 knockdown via RNA
interference in hippocampal cultures resulted in a decrease in
the density of both excitatory and inhibitory synapses.
Here, we focused on the hippocampus to test in vivo the
hypothesis that involvement of CDH13 in the susceptibility to
neurodevelopmental/psychiatric disorders is associated with its
potential role in the modulation of synaptic function. We
investigated CDH13 expression and function in speciﬁc subtypes
of hippocampal neurons in vitro and in vivo. Furthermore, we
describe the electrophysiological and behavioral consequences
of CDH13 deﬁciency in a mouse model of constitutive
Cdh13 inactivation. Finally, by linking alterations in hippocampal
GABAergic synaptic transmission with cognitive deﬁcits, we
provide evidence that supports a critical role for CDH13 in the
synaptic activity of the hippocampal GABAergic circuitry.
MATERIALS AND METHODS
Generation of a constitutive Cdh13 knockout mouse line
A constitutive Cdh13 knockout mouse (Cdh13− /−) was generated through
site-speciﬁc DNA recombination by crossing Cdh13loxP/loxP mice (C57Bl/6N
background) with a constitutive Cre deleter line31 (Supplementary Figure
S1 and Supplementary Table S1). The absence of CDH13 protein in
Cdh13− /− mice was veriﬁed by western blot and immunohistochemistry.
Animal protocols have been approved by the boards of the University of
Würzburg and the government of Lower Franconia, and performed
according to the European Community guidelines for animal care and use.
Adult mice (10–16 weeks) were used, if not indicated otherwise.
Histological methods
In situ hybridization. Single chromogenic in situ hybridization to detect
Cdh13 messenger RNA (mRNA) was carried out on 16 μm coronal brain
sections. Double-ﬂuorescent in situ hybridization was performed to detect
Cdh13 (digoxigenin-labeled) and glutamic acid decarboxylase 1 (Gad1,
ﬂuorescein-labeled) mRNAs.
Immunoﬂuorescence and colocalization assessment. Mice (n=3) were
transcardially perfused, 40 μm free-ﬂoating serial coronal sections gener-
ated and co-stained for CDH13 plus one of the following interneuron
markers: somatostatin (SOM), parvalbumin (PV), calbindin, neuropeptide Y,
vasoactive intestinal peptide, neural nitric oxide synthase (nNOS) and
calretinin. Some sections were triple-stained for CDH13, PV and SOM.
Double immunoﬂuorescence stainings were examined under an inverted
epiﬂuorescence microscope (Olympus, Hamburg, Germany). The numbers
of single- and double-stained cells in single and merged images were
counted using the ImageJ ‘Cell Counter’ plugin.
Immunohistochemistry. For single CDH13 staining, 20 μm sections of
perfusion-ﬁxed brains on slides were incubated with primary antibody.
N-Histoﬁne Simple Stain Mouse MAX PO (G) (Nichirei Biosciences, Tokyo,
Japan) and 3,3′-diaminobenzidine (Roche Diagnostics Deutschland,
Mannheim, Germany) were used for detection.
For single staining of interneuronal markers, immersion-ﬁxed brains
(n=7–9 per genotype) were serially sectioned into 50 μm free-ﬂoating
coronal sections. Sections were treated with heat-induced epitope
retrieval, incubated with primary antibodies against SOM, PV and nNOS
and detected using biotinylated secondary antibodies (Vector Laboratories,
Burlingame, CA, USA), AB complex (Vector Laboratories) and 3,3′-
diaminobenzidine (Roche Diagnostics Deutschland) development. Stained
sections were then analyzed using Stereo Investigator v.11 (MBF
Bioscience, Williston, VT, USA). PV-, SOM- and nNOS-positive cells in the
stratum oriens (SO) were counted with the optical fractionator method.
Immunocytochemistry. Primary hippocampal neuron cultures were pre-
pared from embryonic day 18 (E18) old rats as previously described32 and
maintained in neurobasal media supplemented with B27, penicillin,
streptomycin and L-glutamine (GIBCO-Invitrogen, Darmstadt, Germany).
Fixed (paraformaldehyde) and permeabilized (Triton X-100) cultures were
co-stained for CDH13 together with one of the following synaptic markers:
vesicular glutamate transporter, vesicular GABA transporter, postsynaptic
density protein 95 (PSD95), gephyrin and GABA-A receptor α1 subunit
(GABA-Aα1). Double immunoﬂuorescence stainings were examined under
a Fluoview FV1000 confocal microscope (Olympus).
RNA isolation and semiquantitative RT-PCR
Complementary deoxyribonucleic acid (cDNA) was synthesized using
1–2 μg total RNA from mouse brains (whole brain and hippocampus) of
different ages. A 1:15 dilution of cDNA pool was used for semiquantitative
RT-PCR analysis of Cdh13 expression. The semiquantitative RT-PCR data
were analyzed using comparative quantiﬁcation. Peptidyl prolyl isomerase
(Ppia) and β-actin (Actb) served as reference genes for normalization of
Cdh13 Q-values.
Electrophysiology
Electrophysiological experiments were conducted on horizontal slices
(350-μm thick) from the ventral hippocampus of postnatal day (P) 20–22
mice of both genders. Miniature inhibitory postsynaptic currents (mIPSCs)
were recorded in the presence of Tetrodotoxin (1 μM), 6-cyano-7-
nitroquinoxaline-2,3-dione (CNQX, 5 μM) and D-(-)-2-amino-5-phosphono-
pentanoic acid (D-APV, 100 μM). Miniature excitatory postsynaptic currents
were recorded in the presence of Tetrodotoxin and Picrotoxin (100 μM).
Paired pulse ratio was recorded in the presence of 6-cyano-7-nitroquinoxa-
line-2,3-dione, D-(-)-2-amino-5-phosphonopentanoic acid, 4 mM CaCl2 and
4mM MgCl2. Traces were recorded using a Multiclamp 700B ampliﬁer
(Molecular Devices, Wokingham, UK). Miniature recordings were analyzed
using Mini Analysis Program (Synaptosoft, Decatur, GA, USA). Other traces
were analyzed using Clampﬁt 10.2. Intrinsic cell parameters were recorded
in current clamp using Signal (CED, Cambridge, UK) and traces were
analyzed using Stimﬁt v0.13 following the parameter deﬁnitions used in
Tricoire et al.33
Morphological reconstructions
Brain slices with biocytin-ﬁlled neurons were processed following a
modiﬁed staining protocol based on Marx et al.34 Stained sections were
imaged and somata, apical and basal dendrites of selected pyramidal
neurons were reconstructed in Neurolucida v10 (MBF Bioscience).
Reconstructions were analyzed in NeuroExplorer (MBF Bioscience) for
intrinsic parameters and Sholl analysis.
Behavioral assessment
Four cohorts of adult male Cdh13+/+ (n= 7–10), Cdh13+/− (n= 8–10) and
Cdh13− /− (n= 7–10) mice were subjected to behavioral tests to assess
anxiety-like behavior and conditioned fear responses, depression-like
behavior, social interaction, locomotor activity, attention, impulsivity and
cognitive ﬂexibility. Stress hormone levels were measured from fecal
samples and central blood.
Statistical analysis
Genotype effects were analyzed by univariate analysis of variance (two-
sided) and, in cases of signiﬁcance (Po0.05), post hoc comparisons using
Bonferroni correction for multiple testing. In cases of non-normality and/or
unequal variances, non-parametric statistical analysis using the Kruskal–
Wallis test was performed instead of parametric analysis of variance. For
those behavioral tests with repeated measures, a mixed analysis of
variance was used, with genotype as between-subject factor and time or
testing phase as repeated measure. Data analysis was performed using
Prism 6.04 (GraphPad Software, La Jolla, CA, USA) or SPSS Statistics 21 (IBM,
Armonk, NY, USA). A preliminary analysis revealed that the statistical power
of our experimental setups to detect genotype-dependent differences with
a medium effect size was of at least 0.8.
Detailed descriptions of all the methods are provided in the
Supplementary Information.
RESULTS
CDH13 is located in speciﬁc subtypes of hippocampal
interneurons
We detected Cdh13 mRNA in subregions and distinct cells of the
hippocampus (Figure 1). In particular, the highest cellular
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expression was detected in the SO of the cornu ammonis (CA)
region, whereas weaker labeling was observed in scattered cells of
the CA3 pyramidal layer, as well as the hilus and the granule cell
layer of the dentate gyrus. These in situ hybridization ﬁndings
were complemented with an immunohistochemical analysis of
CDH13 protein expression using an anti-CDH13 antibody which
we validated for speciﬁcity using Cdh13 null mutant mice
(Supplementary Figure S1). Of note, intense cellular immuno-
reactivity was observed in cell bodies located in the SO, in a pattern
which closely resembled Cdh13 mRNA expression. In addition,
CDH13 protein was also distributed in the hippocampus in a
characteristic laminar pattern (Figure 1a), with the strongest
Figure 1. CDH13 expression in murine hippocampus. (a) CDH13 protein and mRNA expression in the hippocampus of the adult mouse,
CDH13 protein and mRNA are present in cell somata of the stratum oriens (SO; a,a’). (ISH picture was shown as preliminary data in a review
article by Rivero et al.;4 reproduced with permission from Elsevier). (b) Double FISH: Cdh13 is localized in Gad1 mRNA-positive cells of the SO
(white arrows: colocalization; green arrows: only Gad1+). (c) IF images: colocalization study of CDH13 and parvalbumin/somatostatin/neural
nitric oxide synthase (white arrows: colocalization, green arrowhead: single stained cell for PV/SOM/nNOS, red arrowhead: single stained cell
for CDH13). (d) Colocalization of CDH13 with neurochemical markers of GABAergic interneurons in the SO of the dorsal (upper panel) and
ventral (lower panel) hippocampus. A higher degree of colocalization is observed in the dorsal part of the hippocampus. n=3; 100%=CDH13+
cells; percentages calculated from median (see Supplementary Figure S2 for details). (e) Triple IF: CDH13 is colocalized with PV and SOM in
some but not in all cells of the SO (white arrow: triple localization, empty arrowhead: double localization). Scale bars, 300 μm in a, 50 μm in a/a’,
b, c and e. CB, calbindin; CR, calretinin; DG, dentate gyrus; FISH, ﬂuorescent in situ hybridization; mRNA, messenger RNA; nNOS, neural nitric
oxide synthase; NPY, neuropeptide Y; PV, parvalbumin; SOM, somatostatin; VIP, vasoactive intestinal peptide.
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staining in the stratum lucidum of CA3 and stratum lacunosum-
moleculare, in the molecular layer and hilus of the dentate gyrus,
as well as along the mossy ﬁber projections.
The unique and distinct cellular pattern of CDH13 labeling in
the hippocampal SO prompted us to ascertain the nature of these
CDH13-positive cells. Their sparse distribution suggested a
GABAergic nature, as it is known that the bodies of a considerable
number of GABAergic inhibitory interneurons are located in this
deep layer of the hippocampus.35 As expected, a double-
ﬂuorescent in situ hybridization approach using probes for
Cdh13 and the interneuron marker Gad1 showed that most of
the Cdh13-positive somata of the SO were indeed interneurons
(Figure 1b).
Hippocampal interneurons are a heterogeneous group of cells
that differ in their morphological and electrophysiological
properties.33 To better identify the nature of the CDH13-
immunoreactive interneurons detected in the SO, we performed
double-immunoﬂuorescence experiments to label CDH13 with
each of seven neurochemical markers (PV, calbindin, calretinin,
SOM, neuropeptide Y, vasoactive intestinal peptide and nNOS)
characteristically expressed in different subpopulations of hippo-
campal interneurons (Figures 1c and d). Initial qualitative
assessment revealed that the extent of coexpression with
CDH13 substantially varied depending on the analyzed inter-
neuron marker (Figure 1c). Next, a stereological approach to
precisely quantify the degree of coexpression (Figure 1d and
Supplementary Figure S2a) was used. The highest levels of
coexpression were found with SOM (63% of CDH13-
immunoreactive cells were also positive for SOM in the dorsal
hippocampus, 49% in the ventral hippocampus) and PV (with 50%
of CDH13-immunoreactive cells being positive for PV in the dorsal
hippocampus, 35% in the ventral part). In contrast, very low levels
of coexpression were found with nNOS (2–6%) and calretinin (4%).
In addition, the percentages of interneurons of each subpopula-
tion that were positive for CDH13 were calculated (Supplementary
Figure S2a). In this case, CDH13 was most frequently found in PV-
(66% dorsal, 31% ventral), SOM- (55% dorsal, 39% ventral) and
neuropeptide Y- (47% dorsal, 35% ventral) immunoreactive cells of
the SO.
The above data indicate that, in the SO, CDH13 is most
frequently found in PV- and SOM-positive cells. PV and SOM are
thought to be representative of two interneuronal subpopulations
that are distinct or have very little overlap. There is no
coexpression of PV and SOM in the cerebral cortex,36 whereas
there is a small degree of overlap in the hippocampus.33 Notably,
we show via triple PV-SOM-CDH13 staining that some, but not all,
of the CDH13-immunoreactive cells of the SO were positive for
both SOM and PV (Figure 1e).
CDH13 is located at inhibitory synapses
To gain further insight into the function of CDH13 in the brain, we
assessed its temporal expression pattern in whole brain as well as
in hippocampus (Figure 2a). Cdh13 mRNA was detected from
E13.5 onwards and increased to reach a peak at P7 to P21 for
whole brain, as well as P14 for hippocampus, times of period that
coincide with synapse formation.30,37 Although previous studies
showed that ectopically expressed CDH13 localized to synapses in
hippocampal primary cultures,30 we explored endogenous label-
ing at the synapse in more detail. Hippocampal neurons at 3 days
in vitro were transfected with a myc-tagged Cdh13.30 Co-staining
for CDH13 and MYC at 14 days in vitro showed an exactly
overlapping punctated pattern and conﬁrmed antibody speciﬁcity
for subsequent co-immunoﬂuorescence analysis (Supplementary
Figure S3). To determine the speciﬁc synaptic localization of
endogenous CDH13, we co-stained hippocampal neurons at
14 days in vitro for CDH13 and the presynaptic markers vesicular
glutamate transporter (VGLUT) or vesicular GABA transporter
(VGAT) (excitatory and inhibitory, respectively) or the postsynaptic
markers PSD95 or gephyrin (excitatory and inhibitory, respectively;
Figure 2b). CDH13 colocalized exactly with the presynaptic marker
VGAT, but not VGLUT. At the postsynaptic side, CDH13 showed
juxtaposed labeling with gephyrin, but not with PSD95. As CDH13
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Figure 2. Temporal expression pattern and subcellular localization of CDH13. (a) Developmental timeline of Cdh13mRNA expression for whole
brain (black bars) and hippocampus (gray bars; mean± s.e.m.; n= 2 for hippocampus E18.5, P7, P21 and adult, for all other time points n= 3).
(b) Immunoﬂuorescence staining of cultured hippocampal neurons for CDH13 (green) and the synaptic markers VGLUT, VGAT, PSD95 or
Gephyrin (red). CDH13-positive puncta are indicated by the triangles, colored yellow for colocalized foci (VGAT) and blue for juxtaposed foci
(Gephyrin). CDH13 localizes at the presynaptic side of inhibitory synapses. Scale bar, 1 μm. (c) Immunoﬂuorescence staining of cultured
hippocampal neurons for CDH13 (green) and GABA-A receptor α1 subunit (GABA-Aα1, red). CDH13-positive puncta are indicated by the
triangles, colored blue for juxtaposition with GABA-Aα1-positive puncta. White arrows indicate puncta that are CDH13-negative and GABA-
Aα1-positive. Scale bar, 1 μm. mRNA, messenger RNA; VGAT, vesicular GABA transporter; VGLUT, vesicular glutamate transporter.
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is coexpressed in a high proportion of PV-positive cells
(Supplementary Figure S2a), we investigated whether CDH13
colocalized with the GABA-A subunit primarily found in synapses
formed by PV-positive cells, GABA-Aα1 (Figure 2c). Indeed, CDH13
puncta were found juxtaposed to GABA-Aα1 puncta, consistent
with a presynaptic (CDH13) and postsynaptic (GABA-Aα1)
localization. Conversely, not all GABA-Aα1-positive puncta were
positive for CDH13, indicating that these puncta originate from
another subpopulation of interneurons that is CDH13-negative.
Together with our ﬁnding that CDH13 is expressed in inhibitory
neurons in the SO, these data provide evidence that, in
hippocampal neurons, CDH13 localizes at the presynaptic
compartment of inhibitory synapses.
Cdh13 knockout mice display increased inhibitory synaptic
transmission
To investigate the functional consequences of CDH13 deﬁciency
for the hippocampal inhibitory network, we generated a
constitutive Cdh13 knockout mouse line (Supplementary Figure S1).
In agreement with a previously reported mouse model of
constitutive CDH13 deﬁciency,38 Cdh13 null mutant (Cdh13− /−)
mice exhibited normal life expectancy and breeding capacity; they
did not present any gross morphological abnormalities of the
brain (Supplementary Figure S4). Weight gain, daily food and
water intake, as well as stress hormone levels were not affected by
genotype (Supplementary Figure S5).
As CDH13 is localized at the presynaptic compartment of
inhibitory synapses, we assessed basal inhibitory synaptic
transmission by recording mIPSCs from CA1 pyramidal cells in
acute slices from P20-22 Cdh13+/+, Cdh13+/− and Cdh13− /− mice
(Figures 3a to c). We found an increased mIPSC frequency in the
Cdh13− /− mice compared with Cdh13+/+ (Cdh13+/+: 3.29 ± 0.47 Hz,
Cdh13− /−: 4.93 ± 0.29 Hz, Po0.001) and Cdh13+/− (3.73 ± 0.29 Hz,
Po0.05), but no change in mIPSC amplitude (Cdh13+/+:
18.25 ± 0.42 pA, Cdh13− /−: 19.31 ± 0.36 pA, P= 0.07). Consistent
with exclusive localization of CDH13 at inhibitory synapses,
miniature excitatory postsynaptic currents were unchanged in
both amplitude (Cdh13+/+: 16.43 ± 0.67 pA, Cdh13+/− :
15.85 ± 0.24 pA, Cdh13− /−: 16.00 ± 0.32 pA, P40.05) and frequency
(Cdh13+/+: 0.34 ± 0.03 Hz, Cdh13+/− : 0.40 ± 0.03 Hz, Cdh13− /−:
0.40 ± 0.04 Hz, P40.05; Figures 3d to f). As our approach was
constitutive rather than interneuron-speciﬁc Cdh13 inactivation,
we aimed to exclude the possibility that knocking out Cdh13 in
CA1 pyramidal cells has any effects on synaptic transmission. To
do this, we prepared organotypic hippocampal slices from wild-
type rats and injected a lentivirus carrying a shRNA against Cdh13
previously validated by Paradis et al.30 into the pyramidal cell layer
of CA1 and then recorded simultaneously from an infected and a
non-infected pyramidal neuron and compared the response to
different stimulation locations (Supplementary Figures S6a, e
and i). We found no difference in inhibitory input from SO
(Supplementary Figures S6b to d) or stratum radiatum
(Supplementary Figures S6f and g). Also, excitatory input from
stimulation of the Schaffer collaterals was unaltered for both
AMPA (Supplementary Figures S6j and k) and NMDA
(Supplementary Figures S6l and m) receptor-mediated input. We
therefore conclude that it is unlikely that the constitutive nature of
our knockout model affects excitatory pyramidal cells directly, and
the observed increase in mIPSC frequency is more likely caused by
the inactivation of Cdh13 in presynaptic inhibitory neurons.
Generally, changes in frequency are explained as either a
change in presynaptic release probability, or as a change in
synapse number. To enable distinction between both possibilities,
we recorded the paired pulse ratio, a measure of the release
probability, of inhibitory synapses following stimulation in SO at
different inter-stimulus intervals. We found an increased paired
pulse ratio in Cdh13− /− compared to Cdh13+/+ mice at the 50 ms
inter-stimulus interval (ISI) only (ISI 50 ms: Cdh13+/+: 0.77 ± 0.03,
Cdh13− /−: 0.93 ± 0.05, Po0.05, Figures 3g and h). An increased
paired pulse ratio is associated with a decreased release
probability. Therefore, the underlying cause for increased mIPSC
frequency in Cdh13− /− mice is unlikely to be a change in release
probability, but rather a change in the number of inhibitory
synapses formed onto CA1 pyramidal cells.
To investigate whether the changes in inhibitory synapses could
be due to altered development of interneuron subtypes we
analyzed the density of PV-, SOM- and nNOS-positive interneurons
of the SO in adult Cdh13− /−, Cdh13+/− and Cdh13+/+ mice. We
found no effect of CDH13 deﬁciency on the densities of nNOS-
positive (which rarely colocalize with CDH13), PV- or SOM-positive
interneurons (P40.05, Supplementary Figure S2b). These results
exclude that the enhanced inhibitory synaptic input on CA1
neurons in Cdh13− /− mice is owing to an increased amount of
interneurons in the SO. Furthermore, no differences in the
hippocampal levels of transmitters (glutamate, GABA, dopamine,
serotonin and norepinephrine) or their metabolites were found
between genotypes (Supplementary Figure S7).
Next, we assessed the general dendritic morphology of CA1
pyramidal cells. To this end, CA1 pyramidal cells were loaded with
biocytin for morphological reconstruction of apical and basal
dendrites (Figure 3i). The basal dendrites were not different
between Cdh13+/+ and Cdh13− /− animals (Figure 3j). The apical
dendrites, on the other hand, were found to be signiﬁcantly more
complex in Cdh13− /− animals at the level of dendritic nodes and
length (nodes: Cdh13+/+: 31.5 ± 1.6, Cdh13− /−: 40.6 ± 1.4, Po0.01;
endings Cdh13+/+: 32.3 ± 1.5, Cdh13− /−: 41.9 ± 1.7, Po0.01; length
Cdh13+/+: 3041.5 ± 436.1 μm, Cdh13− /−: 4521.4 ± 478.9 μm,
Po0.05; Figure 3k, Supplementary Table S2). However, analysis
of the space occupied by the dendrites (Convex Hull analysis,
Supplementary Table S2) showed no difference between geno-
types, indicating that the apical dendrite stays within the same
envelope, but is more branched in Cdh13− /− animals. Intrinsic
electrophysiological properties, such as membrane potential,
input resistance and action potential properties, were identical
between Cdh13+/+ and Cdh13− /− animals (Supplementary Table
S3). Together, these data indicate that CDH13 is a negative
regulator of inhibitory synapse function. Thus, loss of function of
Cdh13 could lead to a distorted excitation/inhibition balance
within the hippocampus.
Behavioral alterations of Cdh13 knockout mice correlate with
hippocampal dysfunction and ADHD phenotypes
We assessed the effects of CDH13 deﬁciency on different
behavioral domains. The analysis revealed no signiﬁcant genotype
effect on any variable measured to assess anxiety- and depression-
like behavior as well as social interaction (Supplementary Figures
S8–S10). We also tested locomotor activity in an open ﬁeld for
30min. In a cohort of mice with prior test experience, we detected
a signiﬁcant genotype effect for distance traveled (P = 0.023,
Figure 4a) and number of rears (P= 0.039, Figure 4b), indicating
that Cdh13− /− mice displayed higher locomotor activity than
Cdh13+/+ mice. These ﬁndings were replicated in a cohort of naive
mice (distance: P= 0.069; rears: P= 0.047). Center time, a measure
of anxiety-like behavior, was not affected by genotype in either
test-experienced or naive cohorts (Figure 4c).
In the ﬁve-choice serial reaction time task (5-CSRTT), which
evaluates attention and impulsivity, acquisition and performance
of the task was similar in all genotypes, as indicated by gradually
increasing accuracy, number of omission errors and pellets eaten,
indicating unaltered attention in Cdh13− /− mice, as well as
decreasing number of premature and timeout responses and
faster response latencies, ﬁndings that support no genotype-
dependent differences in impulsivity (Figure 5 and Supplementary
Figure S11; session effects: all Po0.001). No signiﬁcant genotype
CDH13, cognition and GABAergic function
O Rivero et al
5
Translational Psychiatry (2015), 1 – 11
Figure 4. Cdh13− /− mice display novelty-induced hyperlocomotion but unaltered anxiety-like behavior in the open ﬁeld. (a) Total distance
traveled and (b) number of rears as measures of locomotor activity. (c) Time spent in the center of the open ﬁeld as measure of anxiety-like
behavior. Experienced: n= 7–8 per genotype, naive: n= 10 per genotype. Data are presented as mean± s.e.m. #Po0.1, *Po0.05.
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Figure 3. Hippocampal CA1 neurons from Cdh13 null mutant mice show increased inhibitory synaptic input and morphological changes. (a)
Representative traces of miniature inhibitory postsynaptic currents (mIPSCs) recorded from CA1 pyramidal cells from acute brain slices from
Cdh13+/+, Cdh13+/− and Cdh13− /− mice. (b and c) Cumulative distributions of mIPSC amplitudes (b) and inter-event intervals (IEI; c) from
Cdh13+/+ (n= 19/3), Cdh13+/− (n= 18/3) and Cdh13− /− (n= 23/4) hippocampal CA1 neurons. (d) Representative traces of miniature excitatory
postsynaptic currents (mEPSCs) recorded from CA1 pyramidal cells from acute brain slices of Cdh13+/+, Cdh13+/− and Cdh13− /− mice. (e and f)
Cumulative distributions of mIPSC amplitudes (e) and IEI (f) from Cdh13+/+ (n= 12/3), Cdh13+/− (n= 13/3) and Cdh13− /− (n= 14/3) hippocampal
CA1 neurons. (g) Representative overlaid traces of two IPSCs evoked by stimuli delivered at an inter-stimulus interval (ISI) of 50ms. (h)
Quantiﬁcation of paired pulse ratio following stimulation in SO for Cdh13+/+ (n= 15/4), Cdh13+/− (n= 15/3) and Cdh13− /− (n= 15/3). (i)
Representative reconstructions of hippocampal CA1 neurons from Cdh13+/+ and Cdh13− /− mice. (j and k) Quantiﬁcation of (j) basal dendritic
and (k) apical dendritic nodes and endings for Cdh13+/+ (n= 6) and Cdh13− /− (n= 7). Bar graphs are presented as mean± s.e.m. *Po0.05;
**Po0.01; ***Po0.001. n is shown as number of cells/number of animals.
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effects on any variable measured in the 5-CSRTT were detected.
However, there was a session × genotype interaction for the
number of timeout responses (Figures 5d, P= 0.005), showing that
during the ﬁrst training session with longer stimulus duration of
20 s, Cdh13− /− mice made signiﬁcantly more nose-pokes after an
incorrect response, but only when compared with Cdh13+/− mice.
The assessment of hippocampus-dependent visuospatial mem-
ory in the Barnes maze showed that all mice learned to ﬁnd the
hidden escape box in both acquisition and reversal, as indicated
by gradually decreasing distances, escape latencies and primary
errors throughout the successive trials (signiﬁcant session effects:
all Po0.001; data not shown). There were no session × genotype
interactions, thus data were pooled across sessions to assess
genotype effects. Distance traveled, escape latency and primary
errors (Figures 5e to g) did not differ between genotypes during
acquisition. However, during reversal, where the escape box is
located in a different position, Cdh13− /− mice made signiﬁcantly
more primary errors than Cdh13+/+ mice (P= 0.027), indicating
impaired cognitive ﬂexibility.
During fear conditioning, all genotypes displayed similar
responses to footshock as well as signiﬁcantly increased post-
shock freezing (time effect: Po0.001 compared with pre-shock),
reﬂecting unaltered pain sensitivity and normal acquisition of
conditioned fear in Cdh13− /− mice (Supplementary Figures S12a
and b). Twenty-four hours cued fear memory was signiﬁcantly
impaired in Cdh13− /− mice compared with Cdh13+/+ mice, as
indicated by decreased freezing (genotype main effect: P = 0.047,
Figure 5h) and increased activity (P = 0.081, Supplementary Figure
S12c) during tone presentation. Similarly, in the 48-h contextual
fear memory test, Cdh13− /− mice tended to be more active than
Cdh13+/+ mice (P= 0.094), although freezing duration did not
signiﬁcantly differ between genotypes when exposed to the
original conditioning chamber.
In summary, CDH13 deﬁciency impacts locomotor activity as
well as learning and memory, two behavioral domains frequently
associated with ADHD and related neurodevelopmental disorders.
DISCUSSION
Variation in CDH13 has been associated with a wide range of
neurodevelopmental and psychiatric disorders, ranging from
ADHD to autism spectrum disorders, among others.4 Although
functional single-nucleotide polymorphisms/variants or haplo-
types in CDH13 have yet to be linked to neurodevelopmental/
psychiatric disorders, several copy number variant studies
revealed deletions in ADHD and autism spectrum disorder
patients that may disrupt CDH13 expression and/or
function.19,39,40 Our ﬁndings revealed that inhibitory interneurons
are the primary locus of CDH13 in the murine hippocampus, and
that CDH13 deﬁciency affects hippocampal inhibitory function
and several behavioral domains that are fundamentally altered
across various neuropsychiatric phenotypes, thus contributing to
shed light on the role of CDH13 in the etiopathogenesis of
neurodevelopmental and psychiatric disorders.
We conﬁrmed that in the hippocampal CA region, CDH13 is
predominantly expressed in Gad1 mRNA-positive cells, with
preference for PV- and SOM-positive interneurons, thus allocating
CDH13-related functions to several GABAergic interneuron sub-
populations: axo-axonic cells, basket cells, bistratiﬁed cells, and
also oriens lacunosum-moleculare or hippocampal-septal
projection cells.33,41 Alterations in PV interneurons have previously
been linked to various neuropsychiatric and neurodevelopmental
disorders as well as related animal models.42,43 Furthermore,
SOM-positive interneurons have been implicated in the acquisi-
tion of contextual fear memories and the regulation of
hippocampal synaptic plasticity.44
Figure 5. Cdh13− /− mice exhibit normal attentional performance in the 5-CSRTT but impaired spatial learning in the Barnes maze and deﬁcits
in cued fear memory following delay fear conditioning. (a) % number of correct responses, (b) % number of omission errors, (c) number of
premature responses and (d) number of timeout responses at different stimulus durations in the 5-CSRTT (n= 10 per genotype). (e) Total
distance traveled, (f) escape latency and (g) number of primary errors during acquisition and reversal phase of the Barnes maze (n= 7–10 per
genotype). (h) Freezing (%) duration during presentation of the auditory cue and the original conditioning context following delay fear
conditioning (n= 9–10 per genotype). Data are presented as mean± s.e.m. #Po0.1, *Po0.05, **Po0.01, ***Po0.001. 5-CSRTT, ﬁve-choice
serial reaction time task.
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Along with several other members of the cadherin superfamily
that have been demonstrated to regulate interneuron develop-
ment and hippocampal synaptic function,45–48 CDH13 expression
in the hippocampal CA region suggests a function in interneurons,
particularly at the inhibitory synapse. Furthermore, we conﬁrmed
that Cdh13 mRNA expression reaches its peak in the developing
brain of the mouse between P7 and P21, consistent with recent
observations in lysates from rat cortex,29 thus supporting the view
that CDH13 expression increments coincide with peaking
synaptogenesis in the neocortex.30,37 Our investigations also show
that CA1 neurons from Cdh13− /−mice receive increased inhibitory
input, whereas no changes were found in excitatory input, which
is likely to result in an excitatory–inhibitory imbalance. This notion
supports the view of CDH13 being a critical regulator of inhibitory
function in the hippocampus consistent with its localization in the
GABAergic presynaptic compartment. The ﬁne-tuning of hippo-
campal circuitry depends greatly on the precise activity of the
inhibitory system to control hyperexcitability in the hippocampus,
which displays the lowest seizure threshold of the entire brain.49
However, alterations associated with an altered inhibitory function
are pathophysiologically beyond epilepsy. Multiple lines of
evidence support the role of the inhibitory GABAergic system in
the pathogenesis of psychiatric disorders.42,50 Accordingly, dis-
turbances of the excitatory–inhibitory balance lead to deﬁcits in
information processing and signal gating, two key processes
involved in attentional and executive control.42,51–54 Candidate
risk genes studies further support the view that alterations in the
inhibitory system likely account for a spectrum of neuropsychiatric
manifestations, including schizophrenia, autism spectrum disor-
ders and ADHD.42,55–58 As an example, ErbB4 receptor tyrosine
kinase, which is almost exclusively expressed in interneurons, has
strongly been implicated in schizophrenia.56,59 In the hippocam-
pus, ErbB4 is located at the postsynaptic compartment of
glutamatergic synapses of PV-positive interneurons60 and has a
critical role in the regulation of long-term potentiation at the
SC-CA1 synapse via these interneurons.61,62 In the thalamic
reticular nucleus, ErbB4 is mainly expressed in SOM-positive
interneurons and is important for sensory selection.51 Of note, we
also observed strong expression of Cdh13 in thalamic reticular
nucleus neurons.4 In autism, the different isoforms of the cell
adhesion proteins neurexins and neuroligins have both been
shown to have critical roles in inhibitory synapse function. Of
particular relevance is the observation that neuroligins 2 (ref. 63)
and 3 (ref. 64) have distinct functions depending on the
interneurons with which they form a synapse. Analogous to the
neuroligins, and as we show that CDH13 is expressed in both PV-
and SOM-immunoreactive cells, CDH13 might have distinct
functions depending on the interneurons in which it is expressed.
Although the concentrations of GABA in hippocampus appear
to be unchanged in Cdh13− /− mice, CDH13 deﬁciency may have
effects on the modulation of inhibitory synaptic activity and
synapse turnover. Our electrophysiological ﬁndings support the
view that CDH13 may act as a synapse destabilizer. Therefore, in
the absence of CDH13, stability of GABAergic synapses might be
augmented owing to a reduced synapse turnover, producing an
increase in inhibitory synapse density, consistent with the
observed increase in inhibitory synaptic transmission. The role of
cadherins in synapse (de)stabilization and plasticity has been well
documented.1,65,66 The mechanism whereby CDH13 would
participate in synapse (de)stabilization might involve heterophilic
interactions in trans with elements of the postsynaptic compart-
ment and/or also interactions in cis with presynaptic transmem-
brane molecules in close proximity. Among the potential
candidates to interact with CDH13 in trans is the GABA-Aα1
subunit, expressed in PV-positive hippocampal interneurons and
whose association with CDH13 has already been described in
vascular endothelial cells.67 Transmembrane molecules of the
presynaptic (or postsynaptic) compartments that could potentially
interact with CDH13 include integrin-linked kinase,68 integrins67 or
receptor tyrosine kinases,4 among others. Such interactions may
induce downstream changes in actin cytoskeleton organization,69
which destabilize the GABAergic synapse.
Cdh13 knockdown in dissociated primary hippocampal neurons
was previously reported to lead to a reduced density of both
excitatory and inhibitory synapses, as well as a decrease in
miniature excitatory postsynaptic currents amplitude and
frequency.30 In the present study, we show in organotypic slices
that knockdown using the same shRNA exclusively in excitatory
CA1 pyramidal cells did not affect inhibitory or excitatory input
onto these cells, consistent with the expression pattern of CDH13
restricted to hippocampal CA inhibitory but not excitatory
neurons. In addition, we show that in Cdh13− /− mice, miniature
excitatory postsynaptic currents amplitude and frequency are
unaffected. Together, our data conﬁrm that excitatory synapses
are not directly (via shRNA-mediated knockdown of Cdh13) or
indirectly (secondary to changes in interneuronal activity and/or
connectivity) affected. The difference between the two studies
may thus be caused by the type of experimental model (postnatal
brain sections and organotypic slices vs dissociated cells)
rendering it difﬁcult to accurately extrapolate conclusions from
both studies.
The hippocampus is central to cognition, spatial navigation, as
well as memory formation and speciﬁcally the regulation of
emotional memories.35 Furthermore, altered verbal and visuo-
spatial working memory is one of the neurocognitive alterations
widely described in ADHD.70–72 Other mouse models for
neurodevelopmental disorders, such as Down syndrome or
neuroﬁbromatosis type 1, also present increased inhibition, which
correlates with spatial memory deﬁcits.42,73–75 Remarkably, the
excitation/inhibition imbalance triggered by the loss of CDH13
function in the hippocampus was consistently reﬂected in the
behavior of CDH13-deﬁcient mice. We showed that Cdh13 null
mutants display alterations in cognition and learning/memory
(particularly, spatial memory deﬁcits during the reversal phase of
the Barnes maze when the position of the escape box is changed),
suggesting either reduced cognitive ﬂexibility in Cdh13− /− mice
(that is, inability to change their search strategies during the
reversal phase) or a learning deﬁcit when the difﬁculty of the task
increases. In addition, Cdh13− /− mice display other minor
alterations in conditioned fear responses as well as in the initial
phase of the 5-CSRTT, which support the notion of learning
deﬁcits as a consequence of CDH13 deﬁciency. For example, the
increased number of timeout responses during the training
session may also support the notion of cognitive inﬂexibility in
these mice.76 By contrast, during the 5-CSRTT, no modiﬁcations in
attention or impulsivity were detected in Cdh13− /− mice. In the
context of neurodevelopmental/psychiatric disorders, this sug-
gests that the contribution of CDH13 variation to these disorders
would be restricted to certain behavioral dimensions, that is,
learning ability and cognitive ﬂexibility, whereas other aspects (for
example, attentional processes) would be less affected by CDH13
variation, at least under baseline conditions.
The alteration in cognitive functions observed in Cdh13-
deﬁcient mice are in general mild but not unexpected, given
the observation that single genetic risk variants for neuropsychiat-
ric disorders tend to display very modest effect sizes.77 Moreover,
considering that deﬁcits and impairments associated with
neurodevelopmental disorders, such as ADHD, are more poorly
compensated during childhood, the effects of CDH13 deﬁciency
on mouse behavior might even be more pronounced in
adolescent mice compared with adult animals investigated in
our study. Finally, it is also possible that CDH13 deﬁciency may
induce more extensive inhibitory dysfunction under conditions of
environmental adversity, similar to its role as a cardioprotector
under acute or chronic cardiac stress or its function in angiogen-
esis and tumor growth in a mouse model of mammary tumor.38,78
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Further studies will be necessary to disentangle the contribution
of CDH13 under different environmental conditions in more detail.
Finally, we provided evidence that Cdh13− /− mice display
increased locomotor activity, one of the core phenotypes in
ADHD,79 which is even more pronounced in mice following
adaptation to the environment, suggesting that CDH13 deﬁciency
may impair the hippocampal-dependent learning process that
underlies the habituation to consecutive behavioral tests.80
We are aware that our study presents some limitations.
Although the current work focused on CDH13 in the hippocam-
pus, we and others have previously reported that CDH13 is also
expressed in other regions of the mouse brain.4,29 Therefore, the
use of conditional Cdh13-deﬁcient mice will clarify whether
inactivation of CDH13 in other brain regions and neuronal cells
impacts at the synaptic and behavioral levels. A cell-speciﬁc, such
as PV- or SOM-speciﬁc, Cdh13 knockout will facilitate dissection of
the speciﬁc contribution of CDH13 to each interneuron type
where it is expressed. Furthermore, following this line of reason-
ing, Cdh13 is also expressed in serotonin (5-HT)-speciﬁc neurons of
the raphe complex.4 Genetic variants of CDH13 have been
associated with criminal behavior with extreme violence,23 a
domain that is profoundly inﬂuenced by the brain 5-HT system.81
However, we did not ﬁnd any indication for alterations in
phenotypes related to emotion regulation in Cdh13-deﬁcient
mice including baseline levels of the stress hormone corticoster-
one. This also excludes the possibility that observed alterations in
the cognitive domain are masked by emotional dysregulation.
Finally, no functional CDH13 variants associated with violent
behavior have been identiﬁed yet and it is still unknown whether
the nature of these variants results in a loss or a gain of CDH13
function.
In conclusion, our ﬁndings demonstrate that CDH13 localizes to
the presynaptic compartment of hippocampal GABAergic
synapses and safeguards the excitatory–inhibitory balance in the
CA1 region. CDH13 is thus essential for cognitive ﬂexibility
function and correct memory formation. CDH13 deﬁciency results
in behavioral alterations associated with symptoms observed in
neurodevelopmental disorders such as ADHD, including learning
and memory deﬁcits as well as locomotor hyperactivity. The
present ﬁndings therefore contribute to the understanding of how
dysregulation of CDH13 function may predispose individuals to
ADHD and related comorbidities.
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